Research ArticleClinical Investigations
Multitargeted Tyrosine Kinase Inhibition Produces Discordant Changes Between 99mTc-MDP Bone Scans and Other Disease Biomarkers: Analysis of a Phase II Study of Sunitinib for Metastatic Castration-Resistant Prostate Cancer
Philip J. Saylor, Umar Mahmood, Anchisa Kunawudhi, Matthew R. Smith, Edwin L. Palmer and M. Dror Michaelson
Journal of Nuclear Medicine November 2012, 53 (11) 1670-1675; DOI: https://doi.org/10.2967/jnumed.112.105007
Philip J. Saylor
1Division of Hematology–Oncology, Massachusetts General Hospital (MGH) Cancer Center, Boston, Massachusetts; and
Umar Mahmood
2Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts
Anchisa Kunawudhi
2Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts
Matthew R. Smith
1Division of Hematology–Oncology, Massachusetts General Hospital (MGH) Cancer Center, Boston, Massachusetts; and
Edwin L. Palmer
2Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts
M. Dror Michaelson
1Division of Hematology–Oncology, Massachusetts General Hospital (MGH) Cancer Center, Boston, Massachusetts; and
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 53, Issue 11
November 1, 2012
Multitargeted Tyrosine Kinase Inhibition Produces Discordant Changes Between 99mTc-MDP Bone Scans and Other Disease Biomarkers: Analysis of a Phase II Study of Sunitinib for Metastatic Castration-Resistant Prostate Cancer
Philip J. Saylor, Umar Mahmood, Anchisa Kunawudhi, Matthew R. Smith, Edwin L. Palmer, M. Dror Michaelson
Journal of Nuclear Medicine Nov 2012, 53 (11) 1670-1675; DOI: 10.2967/jnumed.112.105007
Multitargeted Tyrosine Kinase Inhibition Produces Discordant Changes Between 99mTc-MDP Bone Scans and Other Disease Biomarkers: Analysis of a Phase II Study of Sunitinib for Metastatic Castration-Resistant Prostate Cancer
Philip J. Saylor, Umar Mahmood, Anchisa Kunawudhi, Matthew R. Smith, Edwin L. Palmer, M. Dror Michaelson
Journal of Nuclear Medicine Nov 2012, 53 (11) 1670-1675; DOI: 10.2967/jnumed.112.105007
Jump to section
Related Articles
Cited By...
- Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1
- Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer
- A Dose-Ranging Study of Cabozantinib in Men with Castration-Resistant Prostate Cancer and Bone Metastases